pounds studied, dextro-thyroxine showed the greatest disparity between its calorigenic and hypocholesteremic effect. Larson and co-workers12 found no deiodination of dextro-thyroxine in an in vitro system. However, comparative isotope studies on the disposition of d-and 1-thyroxine in the rat by Tapley and co-workers13 revealed not only that d-thyroxine was excreted more rapidly, but also that it was concentrated twice as much in the liver while only one sixth as much in other tissues (e.g., heart muscle) as was 1-thyroxine.
Material and Methods
Outpatients of the University of Chicago Clinics with coronary disease or hypercholesteremia, and on whom monthly values of serum cholesterol were available for 6 months before treatment, were given 4 to 8 mg. of sodium d-thyroxine' daily. The larger dose was used initially, but the 4 or 6 mg. dose was later used, even as the starting dose, when adverse effects on the larger dose became apparent. Basal metabolic rate, pulse rate, and blood pressure were measured initially and at least once more, after about 3 months of treatment. In addition the patients were seen in regular clinic visits and examined for signs of hyperthyroidism or worsening cardiac symptoms at appropriate intervals.
Of 20 patients initially considered for this study, one did not cooperate; three developed a sharp increase in the frequency of angina pectoris and discontinued the treatment; and one patient died suddenly at work, while in the tenth week of treatment. Two of those developing angina and the uncooperative patient were excluded; hence the study included one hypothyroid and 16 euthyroid patients, all followed for at least 10 weeks. weeks or longer. The control level (100 per cent) was based on the mean value for 6 preceding monthly determinations.
Of well-being. Two patients developed an obvious lid lag and tremor of the tongue on the larger dose.
Much more disturbing was the increase in intensity of cardiac symptoms. One man (R.B.) developed severe classical angina of effort for the first time since a myocardial infarction 3 years earlier. Of the patients excluded from the study, one who had a stable anginal syndrome experienced a sharp increase in frequency of pain from once to several times a day, often in the absence of precipitating exertion, on the 8-mg. dose. Another whose anginal pattern had been stable for years also had a decrease in exercise tolerance and the new development of nocturnal angina. Two of these patients could tolerate the drug no better when it was reinstituted 2 weeks later at 4 mg. per day. The last patient was able to tolerate a dose of 2 mg. per day of sodium-d-thyroxine, even though he still felt a questionable and subjective reduc- Comparison between the response to so-JONES, COHEN than was seen with the largest dose of 1-thyroxine.
Discussion
The marked hypocholesteremic effect of thyroid-active compounds is well observed in these 16 euthyroid subjects. Our hypothyroid patient experienced a hypocholesteremic effect much more dramatic with d-thyroxine than on a calorically equivalent maintenance dose of 1-thyroxine. These two observations confirm those first made by Starr.8 9 the serum cholesterol to return to pretreatment values was more often seen after 6 to 9 months at lower dosage levels.
A puzzling alteration in the prothrombin time of patients maintained on Dicumarol therapy was frequently observed early in the course of d-thyroxine therapy.
Although it is clear that a hyper-beta-lipoproteinemia can be partially corrected by the administration of sodium d-thyroxine, the usual caution observed in the administration of thyroid compounds to patients with heart disease is still deserved. In view of the present uncertainty of the goal of serum lipoprotein manipulations in coronary artery disease, the use of this preparation for that disease cannot be recommended without qualifications and should best be reserved for patients free of cardiac symptoms.
